Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2025-07-31 Interim / Quarterly Rep…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Quarterly Appendix 4C Cash Flow Report 5 pages 230.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements for SYNTARA LIMITED for the quarter ended 30 June 2025. It includes consolidated statements of cash flows from operating, investing, and financing activities, reconciliation of cash and cash equivalents, payments to related parties, financing facilities, and estimated cash available for future operating activities. The document is 11,345 characters long, which is substantial and contains actual financial data and analysis for a quarter, not just an announcement or certification. The presence of detailed quarterly financial data and the reference to a specific quarter aligns with the definition of an Interim / Quarterly Report (IR). Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q4 2025
2025-07-31 English
Appendix 4C quarterly webinar 2 pages 143.9KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing an upcoming investor webinar related to the company's Appendix 4C and quarterly update. It mentions the delay and subsequent lodging of the Appendix 4C Quarterly Cash Flow Report for the period ended 30 June 2025. The document does not contain the actual financial statements or substantive financial data but rather announces the event and provides information on how to attend the webinar. The length is about 5,448 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the company's reporting status and an investor event, not the report itself or a detailed financial presentation.
2025-07-31 English
Quarterly update webinar presentation 7 pages 455.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Update' and dated 1st August 2025, indicating it is a periodic report covering recent developments and financial position updates. It contains detailed information about clinical trial progress, regulatory designations, upcoming milestones, market sizes, and cash position. The length is over 7,000 characters, and it includes substantive data and analysis rather than just an announcement or summary. There is no indication that this is an Annual Report or Earnings Release, nor is it a transcript or governance-related document. The content aligns with a comprehensive interim or quarterly report providing financial and operational updates for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2025
2025-07-31 English
Quarterly Shareholder Report 5 pages 260.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Report | June 2025' and provides a detailed summary of the company's activities and financial performance for the quarter ended 30 June 2025. It includes substantive financial data such as cash balances, net cash outflows, R&D expenditure, and operational updates. The content covers clinical trial progress, regulatory designations, and financial metrics for the quarter, which is consistent with an Interim / Quarterly Report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or summary. There is no indication that this is merely an announcement of a report or a certification document. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2025
2025-07-29 English
Application for quotation of securities - SNT 6 pages 18.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) announcement used to apply for quotation of securities. It details the issuance and quotation of new securities resulting from options being exercised or convertible securities being converted. The document includes specifics such as the number of securities, issue date, and whether the securities rank equally with existing securities. It also mentions that the securities were issued under an employee incentive scheme and includes details about key management personnel involved. This type of document is a formal announcement related to changes in the company's capital structure, specifically the issuance and quotation of new shares. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length (6256 characters) and content confirm it is the announcement itself, not just a report publication or regulatory filing.
2025-07-29 English
First participant dosed in SNT-9465 Phase 1a/b trial 3 pages 201.1KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing the dosing of the first participant in a Phase 1a/b clinical trial for a drug candidate (SNT-9465) by Syntara Limited. It provides details about the trial design, drug development status, and future plans, but does not contain any financial data, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any form of financial statement. It is also not a regulatory filing or certification. The document is a corporate announcement about clinical trial progress and drug development milestones, which fits best under the category of a general regulatory announcement or miscellaneous corporate update. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for such announcements that do not fit other specific categories.
2025-07-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.